Skip to content
Search

Latest Stories

Supply alert for Levomepromazine 25mg/1ml solution for injection

pharmacy.biz Staff
By pharmacy.biz StaffFeb 13, 2020
pharmacy.biz Staff
See Full Bio

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for Levomepromazine (Nozinan) 25mg/1ml solution for injection.

The solution for injection by Sanofi is currently out of stock and the stock is expected to resume in the week commencing February 24, 2020.

“The only other UK supplier, Wockhardt, currently have stock. As levomepromazine is widely used as a second line agent for terminal agitation and intractable nausea and vomiting, specialist palliative care teams should be consulted on management options should stock run out,” a Specialist Pharmacy Service (SPS) statement read.

Related News

PHOENIX expands operations with new depot in Aberdeen
News

PHOENIX opens new depot in Aberdeen

Paul Bennett
News

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Trump signs executive order to accelerate US-based pharmaceutical manufacturing plants
News

Trump signs executive order to encourage US drug manufacturing

Pharmacist declining participation in assisted dying under new UK legislation
News

Pharmacists to have choice to opt-out of assisted dying process

More For You

Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
After US and EU, UK approves Bavarian Nordic’s chikungunya vaccine

Bavarian Nordic plans to launch the vaccine in the UK in summer 2025

Getty Images

Chikungunya vaccine Vimkunya approved for use in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Vimkunya, a vaccine developed by Bavarian Nordic A/S to prevent chikungunya disease in people aged 12 years and older.

The UK approval follows earlier approvals by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025, making this the third regulatory green light for the vaccine.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
Many patients report inaccuracies or missing details in their NHS medical records

Inaccurate information can result in serious harm or even death, warns Healthwatch England.

Image Credit: Getty Images

1 in 4 adults have spotted errors in their NHS medical records, survey finds

Healthwatch England has raised the alarm over the risks posed by inaccurate medical records as research reveals widespread errors in NHS patient information.

Commissioned by Healthwatch England and conducted by BMG Research, the survey polled a representative sample of 1,800 adults in England between 24 and 27 March 2025.

Keep ReadingShow less
RPS and HEIW extend independent prescribing learning programme for pharmacists in Wales

The programme is designed to support pharmacists delivering the Pharmacy Independent Prescribing Service in Wales.

gettyimages

Independent prescribing learning programme for pharmacists in Wales extended till 2028

The Royal Pharmaceutical Society (RPS) and Health Education and Improvement Wales (HEIW) have announced a three-year extension of their successful learning programme designed to support pharmacists delivering the Pharmacy Independent Prescribing Service (PIPS) in Wales.

Originally launched in 2024, the programme equips pharmacists with the essential knowledge, skills, and confidence needed to provide excellent patient care as independent prescribers.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc